Prostate cancer is the most frequently diagnosed cancer and is the second leading cause of cancer-related deaths in American men. Although the early serum detection of prostate-specific antigen (PSA) plays important roles on early diagnosis, it may not distinguish prostate cancer from benign diseases. Recently, a novel protein, which contains 339aa, named STEAP (six-transmembrane epithelial antigen of the prostate), was identified in advanced prostate cancer. STEAP is unique among the currently known prostate cancer markers because of its putative secondary structure, from which one may predict that it functions as a potential channel protein. STEAP is strongly expressed in advanced prostate cancer and some extent expression in other cancers, such as colon and ovarian cancer cell lines.
Suitable for use in Western Blot. Other applications not tested.
Western Blot: 0.5-2ug/ml
Optimal dilutions to be determined by the researcher.
Storage and Stability:
May be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.